141 related articles for article (PubMed ID: 37994242)
1. Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial.
Lee YJ; Lee SH; You SC; Lee YH; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
Diabetes Obes Metab; 2024 Mar; 26(3):829-839. PubMed ID: 37994242
[TBL] [Abstract][Full Text] [Related]
2. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
Lee YJ; Cho JY; You SC; Lee YH; Yun KH; Cho YH; Shin WY; Im SW; Kang WC; Park Y; Lee SY; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
Eur Heart J; 2023 Mar; 44(11):972-983. PubMed ID: 36529993
[TBL] [Abstract][Full Text] [Related]
3. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS;
JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
Kim BK; Hong SJ; Lee YJ; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Cho YH; Lee SJ; Ahn CM; Kim JS; Ko YG; Choi D; Jang Y; Hong MK;
Lancet; 2022 Jul; 400(10349):380-390. PubMed ID: 35863366
[TBL] [Abstract][Full Text] [Related]
5. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial.
Lee B; Hong SJ; Rha SW; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Kim HK; Kim U; Choi YJ; Lee YJ; Lee SJ; Ahn CM; Ko YG; Kim BK; Choi D; Hong MK; Jang Y; Kim JS
Atherosclerosis; 2023 Dec; 386():117373. PubMed ID: 37995599
[TBL] [Abstract][Full Text] [Related]
6. Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis.
Kim BG; Lee SJ; Lee YJ; You SC; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Cho YH; Kim JS
Sci Rep; 2023 Nov; 13(1):20157. PubMed ID: 37978309
[TBL] [Abstract][Full Text] [Related]
7. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.
Lee SH; Lee YJ; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Park KH; Lee JH; Choi YJ; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
J Am Coll Cardiol; 2023 Apr; 81(14):1339-1349. PubMed ID: 37019580
[TBL] [Abstract][Full Text] [Related]
8. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial.
Park JI; Lee SJ; Hong BK; Cho YH; Shin WY; Lim SW; Kang WC; Park Y; Lee SY; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS;
EClinicalMedicine; 2023 Apr; 58():101933. PubMed ID: 37090440
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
Park SY; Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC
J Clin Endocrinol Metab; 2024 Jun; 109(7):1883-1890. PubMed ID: 38175670
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Shin KH; Choi HD
Am J Cardiovasc Drugs; 2022 Jul; 22(4):395-406. PubMed ID: 34927215
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Moon JS; Park IR; Kim SS; Kim HS; Kim NH; Kim SG; Ko SH; Lee JH; Lee I; Lee BK; Won KC
Diabetes Metab J; 2023 Nov; 47(6):818-825. PubMed ID: 38043782
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
16. Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial.
Amarenco P; Kim JS; Labreuche J; Charles H; Giroud M; Lee BC; Lavallée PC; Mahagne MH; Meseguer E; Nighoghossian N; Steg PG; Vicaut É; Bruckert E;
Stroke; 2022 Nov; 53(11):3260-3267. PubMed ID: 36154103
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
18. Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.
Cha JJ; Hong SJ; Kim JH; Lim S; Joo HJ; Park JH; Yu CW; Lee PH; Lee SW; Lee CW; Moon JY; Lee JY; Kim JS; Park JS; Lee K; Lim SY; Na JO; Cho JM; Kim SY; Lim DS
Am Heart J; 2023 Jul; 261():45-50. PubMed ID: 36934981
[TBL] [Abstract][Full Text] [Related]
19. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.
Rivers SM; Kane MP; Busch RS; Bakst G; Hamilton RA
Endocr Pract; 2007; 13(1):11-6. PubMed ID: 17360295
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
